causal
IRA Shifted Investment Away From Small-Molecule Oncology
Because the IRA shortens revenue duration, most investment firms have shifted dollars away from small-molecule oncology, since five years at the tail of a product can represent half of an asset's NPV and cancer drugs need long trials to move to frontline use.
causalpending
Speaker
RodEvidence Quote
“most firms have shifted dollars away from oncology and specifically small molecules because of the law.”
Created: 11/13/2026, 1:54:32 PM
Your notes
Loading notes...